Corcept (CORT) Chief Accounting Officer Reports Option Exercise and 10b5-1 Sales
Rhea-AI Filing Summary
Corcept Therapeutics (CORT) insider Joseph D. Lyon, Chief Accounting & Technology Officer, reported multiple transactions on 09/02/2025 and 09/03/2025. He exercised a stock option with a $13.56 strike for 5,000 shares on 09/02/2025, increasing derivative-based beneficial ownership to 26,571 shares. On the same day he sold a total of 5,000 shares under a 10b5-1 plan (weighted average sale prices noted at $70.2386 and $70.7571), purchased 200 shares under the company Purchase Plan at the closing price ($71.38), received 200 restricted shares at $0 under the Purchase Plan, and had 189 shares withheld to satisfy tax withholding upon vesting. The reporting person adopted the 10b5-1 plan on 08/30/2024. All reported holdings are direct.
Positive
- Exercise of options at $13.56 increases long-term alignment with shareholders by converting low-strike options into owned shares
- Use of an established 10b5-1 plan (adopted 08/30/2024) indicates pre-planned, rule-compliant insider sales
- Participation in the Purchase Plan (200 shares bought) and receipt of restricted shares shows continued ownership accumulation and retention incentives
Negative
- Net sales of 5,000 shares under the 10b5-1 plan reduce the Reporting Person's direct share count
- 189 shares withheld for tax withholding reduced the immediate net increase in owned shares following vesting
Insights
TL;DR: Routine insider exercise and sales under a 10b5-1 plan, modest net change in direct holdings; not materially dilutive.
The Reporting Person exercised a low-strike option ($13.56) for 5,000 shares, realizing intrinsic value given market prices around $70–$71. Concurrent sales under a pre-existing 10b5-1 plan removed 5,000 shares from his holdings at weighted average prices reported. He also purchased 200 shares via the company Purchase Plan and received 200 restricted shares granted under that plan, offset partially by 189 shares withheld for taxes. These are standard compensation and trading-plan activities with limited immediate balance-sheet or market-impact implications for the issuer.
TL;DR: Transactions follow governance best practices: use of 10b5-1 plan and clear tax withholding disclosures.
The filing discloses an established 10b5-1 plan adopted 08/30/2024 and shows routine option exercise and plan-based sales. Grant and Purchase Plan shares include one-year vesting conditions. Reporting is timely and includes weighted-average sale prices and withholding for taxes, consistent with transparent insider reporting and compensation-plan mechanics.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 189 | $71.38 | $13K |
| Exercise | Stock option (right to buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $13.56 | $68K |
| Sale | Common Stock | 4,895 | $70.2386 | $344K |
| Sale | Common Stock | 105 | $70.7571 | $7K |
| Grant/Award | Common Stock | 200 | $71.38 | $14K |
| Grant/Award | Common Stock | 200 | $0.00 | -- |
Footnotes (1)
- Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.74 to $70.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on September 2, 2025 was used to calculate the withholding obligation. Fully exercisable.
